Ebronucimab vs QLC7401

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline

Ebronucimab

Marketed by Hubei Jumpcan Pharmaceutical and partners

Phase 3 in Atherosclerotic Cardiovascular Diseasemonoclonal antibody
Partial signal

NCT05255094 · Phase 3 · completed

The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 464 participants, providing a strong experimental design. Its primary endpoint was a laboratory lipid measure rather than a hard clinical outcome. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source.

Reported efficacy

Percentage change from baseline of serum LDL-C level (At week 12): LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001). (met)

Result source: NCT05255094

QLC7401

Developed by Suzhou Ribo Life Science and partners

Phase 3 in Atherosclerotic Cardiovascular DiseaseRNAi (siRNA)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: October 2027 · NCT07444086 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEbronucimabQLC7401
LDL-C, % change—Not posted · NCT05260411—Trial running · NCT07444086
Non-HDL-C, % change—Not posted · NCT05260411—Trial running · NCT07444086
ApoB, % change—Not posted · NCT05260411—Trial running · NCT07444086
Lp(a), % change—Not posted · NCT05260411—Trial running · NCT07444086
3-point MACE (% with event)—Not posted · NCT05260411—Trial running · NCT07444086

LDL-C, % change

Ebronucimab
—Not posted · NCT05260411
QLC7401
—Trial running · NCT07444086

Non-HDL-C, % change

Ebronucimab
—Not posted · NCT05260411
QLC7401
—Trial running · NCT07444086

ApoB, % change

Ebronucimab
—Not posted · NCT05260411
QLC7401
—Trial running · NCT07444086

Lp(a), % change

Ebronucimab
—Not posted · NCT05260411
QLC7401
—Trial running · NCT07444086

3-point MACE (% with event)

Ebronucimab
—Not posted · NCT05260411
QLC7401
—Trial running · NCT07444086
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

QLC7401: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ebronucimab

LDL-C -59.13% @ 12wk450 mg Q4W
percent change · % of baseline
No placebo or comparator arm
NCT05255094 · Phase 3 · sponsor-reported, not registry data
show 1 more result
-60.43% @ 12wk150 mg Q2W
NCT05255094 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ebronucimab's landscape · QLC7401's landscape